2,2'-((3,3'-二甲氧基(1,1'-联苯)-4,4'-二基)二亚胺)二-苯甲酸 | 52962-95-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,2'-((3,3'-二甲氧基(1,1'-联苯)-4,4'-二基)二亚胺)二-苯甲酸
• 英文名称: redoxal
• 英文别名: NSC73735；2-[4-[4-(2-carboxyanilino)-3-methoxyphenyl]-2-methoxyanilino]benzoic acid
• CAS: 52962-95-5
• 化学式: C₂₈H₂₄N₂O₆
• 分子量: 484.508
• InChiKey: IQZIRNIZQHVBMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• 海关编码：
  2922509090

文献信息

• NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS
  申请人：MUTHUPPALANIAPPAN Meyyappan

  公开号：US20110275603A1

  公开（公告）日：2011-11-10

  The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.

  本发明提供了脱氢鸟苷酸脱氢酶抑制剂，其制备方法，含有它们的药物组合物以及治疗、预防和/或改善疾病或障碍的方法，其中已知抑制脱氢鸟苷酸脱氢酶具有益处效果。
• COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES
  申请人：Cardone Michael H.

  公开号：US20120225851A1

  公开（公告）日：2012-09-06

  The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia′, Ib′, Ic′, or II′ (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia′, Ib′, Ic′, or II′. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

  本发明涉及一种化疗癌症的治疗方法，其中将Ia'、Ib'、Ic'或II'的化合物（作为一组称为BH3Is）用于治疗哺乳动物的B细胞淋巴瘤或其他造血系统癌症，包括与MCL-1相关的疾病。在另一方面，本发明提供了一种治疗特定类型的造血系统癌症，例如B细胞淋巴瘤的方法，使用从由Ia、Ib、Ic或II的化合物中选择的一种或多种化合物与其他治疗方法，例如一类被称为26S蛋白酶体抑制剂的治疗剂的组合，例如Bortezomib。在另一方面，本发明涉及使用包括Ia'、Ib'、Ic'或II'的一种或多种化合物的药物组合物进行自身免疫治疗。在另一方面，本发明涉及识别化合物的方法，例如BH3类似物类的化合物，具有预测体内对B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病的疗效的独特的体外特性。
• 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES
  申请人：Eutropics Pharmaceuticals, Inc.

  公开号：US20150216862A1

  公开（公告）日：2015-08-06

  The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapes, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease. Illustrative compounds are those of Formula II:

  本发明涉及一种化疗癌症的治疗方法，其中将化合物（BH3Is）用于治疗哺乳动物的B细胞淋巴瘤或其他造血系统癌症，包括与MCL-1相关的疾病。本发明还提供了一种治疗造血系统癌症（如B细胞淋巴瘤）的方法，该方法使用一个或多个披露的化合物与其他治疗方法（例如26S蛋白酶抑制剂，例如博来佐米布）的组合。本发明还涉及使用含有一个或多个披露的化合物的制药组合物进行自身免疫治疗。本发明还涉及识别化合物的方法，例如BH3类似物类的化合物，这些化合物具有预测体内对B细胞淋巴瘤肿瘤和其他癌症以及自身免疫疾病有效性的独特体外性质。其中一些示例化合物为II式：
• Yeast screens for agents affecting protein folding
  申请人：The University of Chicago

  公开号：EP1793001A2

  公开（公告）日：2007-06-06

  Screening methods for identifying substances that provide therapeutic value for various diseases associated with protein misfolding are provided. Genetic and chemical screening methods are provided using a yeast system. The methods of the invention provide a rapid and cost-effective method to screen for compounds that prevent protein misfolding and/or protein fibril formation and/or protein aggregation which includes numerous neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, Huntington's disease as well as non-neuronal diseases such as type 2 diabetes.

  本研究提供了筛选方法，以确定对与蛋白质错误折叠有关的各种疾病有治疗价值的物质。本发明提供了使用酵母系统的遗传和化学筛选方法。本发明的方法提供了一种快速、经济有效的方法，用于筛选能防止蛋白质错误折叠和/或蛋白质纤维形成和/或蛋白质聚集的化合物，这些疾病包括帕金森病、阿尔茨海默病、亨廷顿病等多种神经退行性疾病以及 2 型糖尿病等非神经元疾病。
• Ligands that target Plasmodium sporozoite binding sites on CD81 and therapeutic methods using them
  申请人：American University In Cairo (AUC)

  公开号：US10548895B2

  公开（公告）日：2020-02-04

  The invention pertains to ligands that bind to CD81 and that inhibit or block Plasmodium attachment to CD81, compositions and methods for preventing, inhibiting or treating infection by Plasmodium and ligands that target a Plasmodium binding site on CD81 and methods of making and using them. A series of ligand binding sites on the large extracellular loop of the open conformation of CD81 have been identified. Several important sites were located in regions identified by mutational studies to be the site of Plasmodium binding. Ligands that recognize these sites were identified. Linking together two or three ligands that bind with low or moderate affinities to different structurally unique sites on a target protein were used to generate small molecule ligand conjugates that exhibit very high affinities to their CD81 targets. Hybrid ligand molecules were also designed using fragment-based drug design methods to generate analogs of the ligands that bind more tightly to the protein than the parent compounds. Identification and design of groups of compounds that bind to CD81 for use as therapeutics for treating patients infected by Plasmodium and pathogens that interact with CD81. By binding to CD81, these molecules can block 1) Plasmodium attachment and entry into cells (infection), especially hepatocytes; 2) block or inhibit inflammatory responses caused by Plasmodium, and 3) block or inhibit the induction of other pathologies associated with Plasmodium infection.

  本发明涉及与 CD81 结合并能抑制或阻断疟原虫附着于 CD81 的配体，用于预防、抑制或治疗疟原虫感染的组合物和方法，以及靶向 CD81 上疟原虫结合位点的配体及其制造和使用方法。CD81 开放构象细胞外大环上的一系列配体结合位点已被确定。几个重要的位点位于通过突变研究确定为疟原虫结合位点的区域。识别这些位点的配体也已确定。将与靶蛋白上不同结构独特位点具有低度或中度亲和力的两种或三种配体连接在一起，可生成与 CD81 靶点具有极高亲和力的小分子配体共轭物。此外，还利用基于片段的药物设计方法设计了混合配体分子，以生成比母体化合物与蛋白质结合更紧密的配体类似物。鉴定和设计与 CD81 结合的化合物组，用于治疗受疟原虫感染的病人和与 CD81 有相互作用的病原体。通过与 CD81 结合，这些分子可以：1）阻止疟原虫附着和进入细胞（感染），特别是肝细胞；2）阻止或抑制疟原虫引起的炎症反应；3）阻止或抑制诱发与疟原虫感染有关的其他病症。